Know Cancer

or
forgot password

Prospective, Multicentre, Non-interventional (Observational) Study of VANTAS® for the Treatment of Patients With Advanced Prostate Cancer.


N/A
18 Years
N/A
Open (Enrolling)
Male
Prostate Cancer

Thank you

Trial Information

Prospective, Multicentre, Non-interventional (Observational) Study of VANTAS® for the Treatment of Patients With Advanced Prostate Cancer.


Inclusion Criteria:



- Male patients for whom hormone treatment for advanced prostate cancer is indicated

- Age > 18 years.

- Documented elevated PSA levels.

Exclusion Criteria:

Contraindications for Vantas® (in accordance with Summary of Product Characteristics
(SmPC))

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Treatment duration follow-up for each patient.

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

Thomas Björk, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Urology Dep. Skane University Hospital, Malmoe, Sweden

Authority:

Sweden: Regional Ethical Review Board

Study ID:

THE VANTAS STUDY

NCT ID:

NCT01574846

Start Date:

January 2011

Completion Date:

June 2014

Related Keywords:

  • Prostate Cancer
  • Prostatic Neoplasms

Name

Location